Published: Jun, 2015
According to a new market report published by Transparency Market Research “Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022,” the global glioblastoma treatment market was valued at USD 0.34 billion in 2013 and is estimated to reach USD 0.91 billion by 2022 at a CAGR of 11.4% from 2014 to 2022.
Browse the full Pipeline Review of Glioblastoma Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2022 report at https://www.transparencymarketresearch.com/pipeline-review-of-glioblastoma-treatment-market.html?
According to Columbia University Medical Center, GBM is the most malignant form of high-grade astrocytoma and is observed to be the most common adult primary brain tumor and make up approximately half of all astrocytomas. According to American Brain Tumor Association, there are two types of glioblastomas which are primary and secondary. Increasing incidence of glioblastoma multiforme is one of the prime factor driving the growth of the market globally. For instance, according to the U.S National Cancer Institute, in year 2015 22,850 cases are expected growing at 1.4% rate compared to 2014 and around 15,320 deaths growing at 2.6% compared to last year. GBM is considered as the most aggressive form of brain cancer which grows rapidly and develops glioma that represents overall 15.4% of all primary brain tumors and about 60% - 75% of all astrocytoma.
The global glioblastoma treatment market, by drugs was valued at USD 341.4 million in 2013 and is anticipated to reach USD 910.9 million by 2022, expanding at a CAGR of 11.4% from 2014 to 2022. Factors such as rising geriatric population, various organizations generating awareness coupled with introduction of novel therapies are driving the growth of this market. In addition, rising awareness against various types of brain tumors, development in drug delivery technologies and combination of modern diagnostic techniques are also supporting the growth of the market.
Temozolomide is the leading molecule in the GBM treatment market accounting for the largest market share in 2013. There are limited therapies available in the market for the treatment of GBM and most of them with overall patient’s survival rate from six to 14 months. Hence, the current pipeline of GBM therapeutics is strong and equipped with biologics, small molecules, devices, surgeries, and immunotherapy. In the current scenario, the pipeline review of glioblastoma seems to be strong as more than 50 molecules are in phase I and phase II clinical trials. The most promising drugs in phase III trials are Rindopepimut or CDX-110 (Celldex Therapeutics) and DCVax-L (Northwest Biotherapeutics). These molecules have performed well in phase II of the clinical trials in terms of exceeding the overall survival rate.
North America and Europe dominated the global GBM market in 2013 majorly due to rising incidences of GBM in the regions coupled with technological advancements. According to World Health Organization (WHO), the incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the North America and Europe. GBM accounts for 12 to 15 % of all intracranial tumors and 50 to 60 % of astrocytic tumors. Thus, owing to the above mentioned factors the GBM market in North America and Europe is expected to retain its dominant position during the forecast period from 2014 – 2022. Asia Pacific is been estimated to be the most lucrative market for GBM due to increasing incidences of brain tumor in Asia Pacific countries such as China and others.
Merck & Co., Inc., F. Hoffmann-Le Roche AG, and Arbor Pharmaceuticals, LLC are the key players dominating the global GBM treatment market in 2013. Temodar (temozolomide) manufactured by Barr Pharmaceuticals, a subsidiary of Merck & Co. has dominated the global GBM treatment market in 2013 as it was the only available chemotherapy post radiation treatment. However, in 2012 the drug had lost its exclusivity thereby reducing the market share of the company in 2013 compared to the previous year. Teva Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Ltd., Amneal Pharmaceuticals. LLC, and others are the other players having presence in the global GBM market.
The pipeline review of glioblastoma treatment market has been segmented as below:
Global Glioblastoma Treatment Market Revenue and Forecast, by Drugs
- Bevacizumab (Avastin)
- Temozolomide (Temodar and Temodal and Temcad)
- Carmustine (BiCNU)
Global Glioblastoma Treatment Market Revenue and Forecast, by Geography
- North America
- Asia Pacific
- Rest of the World
Global Pipeline Review of Glioblastoma Treatment
Late Stage (Phase III)
- Rindopepimut (CDX-110)
Early Stage (Phase I, II and Pre clinical)
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453